Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulodexide for postprandial dyslipidemia in type 2 diabetes
NL-OMON41342Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2014
- Countries
- 1
01
Overview
Single-arm trial of sulodexide in type 2 diabetes mellitus (T2DM), dyslipidemia and hypertriglyceridemia, sponsored by Amsterdam University Medical Center. Primary endpoint: Normalization of postprandial hypertriglyceridemia. Started Apr 2014; status: active, not recruiting.
02
Drugs
sulodexide
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemiahypertriglyceridemia
Beyond the preview
Go deeper on NL-OMON41342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41342.